BR9709915A - Composto composição farmacêutica utilização do composto e processos para o tratamento ou a prevençao de distúrbios fisiológicos asociados com um excesso de taquiquininas e para preparação do composto - Google Patents

Composto composição farmacêutica utilização do composto e processos para o tratamento ou a prevençao de distúrbios fisiológicos asociados com um excesso de taquiquininas e para preparação do composto

Info

Publication number: BR9709915A
Authority: BR; Brazil
Prior art keywords: compound; tachykinins; prevention; excess; processes
Prior art date: 1996-06-21

Application number

BR9709915A

Other languages

English (en)

Inventor

Raymond Baker

Neil Roy Curtis

Jason Matthew Elliott

Timothy Harrison

Gregory John Hollingworth

Philip Stephen Jackson

Janusz Jozef Kulagowski

Eileen Mary Seward

Christopher John Swain

Brian John Williams

Original Assignee

Merck Sharp & Dohme

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-06-21

Filing date

1997-06-17

Publication date

1999-08-10

1996-06-21 Priority claimed from GBGB9613108.1A external-priority patent/GB9613108D0/en

1996-12-02 Priority claimed from GB9625051A external-priority patent/GB9625051D0/en

1996-12-20 Priority claimed from GBGB9626593.9A external-priority patent/GB9626593D0/en

1997-01-24 Priority claimed from GB9701459A external-priority patent/GB9701459D0/en

1997-05-23 Priority claimed from GBGB9710747.8A external-priority patent/GB9710747D0/en

1997-05-23 Priority claimed from GBGB9710748.6A external-priority patent/GB9710748D0/en

1997-05-23 Priority claimed from GBGB9710743.7A external-priority patent/GB9710743D0/en

1997-06-17 Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme

1999-08-10 Publication of BR9709915A publication Critical patent/BR9709915A/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pain & Pain Management (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Psychiatry (AREA)
Rheumatology (AREA)
Hospice & Palliative Care (AREA)
Otolaryngology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

BR9709915A 1996-06-21 1997-06-17 Composto composição farmacêutica utilização do composto e processos para o tratamento ou a prevençao de distúrbios fisiológicos asociados com um excesso de taquiquininas e para preparação do composto BR9709915A (pt)

Applications Claiming Priority (8)

Application Number	Priority Date	Filing Date	Title
GBGB9613108.1A GB9613108D0 (en)	1996-06-21	1996-06-21	Therapeutic agents
GB9625051A GB9625051D0 (en)	1996-12-02	1996-12-02	Therapeutic agents
GBGB9626593.9A GB9626593D0 (en)	1996-12-20	1996-12-20	Therapeutic agents
GB9701459A GB9701459D0 (en)	1997-01-24	1997-01-24	Therapeutic agents
GBGB9710747.8A GB9710747D0 (en)	1997-05-23	1997-05-23	Therapeutic agents
GBGB9710748.6A GB9710748D0 (en)	1997-05-23	1997-05-23	Therapeutic agents
GBGB9710743.7A GB9710743D0 (en)	1997-05-23	1997-05-23	Therapeutic agents
PCT/GB1997/001630 WO1997049710A1 (en)	1996-06-21	1997-06-17	Spiro-piperidine derivatives and their use as therapeutic agents

Publications (1)

Publication Number	Publication Date
BR9709915A true BR9709915A (pt)	1999-08-10

Family

ID=27562932

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BR9709915A BR9709915A (pt)	1996-06-21	1997-06-17	Composto composição farmacêutica utilização do composto e processos para o tratamento ou a prevençao de distúrbios fisiológicos asociados com um excesso de taquiquininas e para preparação do composto

Country Status (19)

Country	Link
US (1)	US6071927A (pt)
EP (1)	EP0906315A1 (pt)
JP (1)	JP2000510153A (pt)
KR (1)	KR20000022060A (pt)
AU (1)	AU722541B2 (pt)
BG (1)	BG102998A (pt)
BR (1)	BR9709915A (pt)
CA (1)	CA2257964A1 (pt)
CZ (1)	CZ424798A3 (pt)
EA (1)	EA001574B1 (pt)
EE (1)	EE9800459A (pt)
IL (1)	IL126900A0 (pt)
NO (1)	NO985977L (pt)
NZ (1)	NZ332777A (pt)
PL (1)	PL330235A1 (pt)
SK (1)	SK175398A3 (pt)
TR (1)	TR199802667T2 (pt)
WO (1)	WO1997049710A1 (pt)
YU (1)	YU59098A (pt)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1997019084A1 (en) *	1995-11-23	1997-05-29	Merck Sharp & Dohme Limited	Spiro-piperidine derivatives and their use as tachykinin antagonists
WO1998002158A1 (en)	1996-07-17	1998-01-22	Merck & Co., Inc.	Alteration of circadian rhythmicity with a tachykinin antagonist
GB9625843D0 (en) *	1996-12-12	1997-01-29	Merck & Co Inc	Phenyl spiroethercycloalkyl tachykinn receptor antagonists
US5929094A (en) *	1996-10-25	1999-07-27	Merck & Co., Inc.	Heteroaryl spiroethercycloalkyl tachykinin receptor antagonists
US5977104A (en) *	1996-12-02	1999-11-02	Merck Sharp & Dohme Ltd.	Use of NK-1 receptor antagonists for treating bipolar disorders
JP2001504852A (ja) *	1996-12-02	2001-04-10	メルクシヤープエンドドームリミテツド	双極性障害の治療のためのｎｋ−１受容体拮抗薬の使用
AU744261B2 (en) *	1997-04-24	2002-02-21	Merck Sharp & Dohme Limited	Use of NK-1 receptor antagonists for treating eating disorders
GB9716463D0 (en) *	1997-08-04	1997-10-08	Merck Sharp & Dohme	Therapeutic agents
WO1999007375A1 (en) *	1997-08-04	1999-02-18	Merck Sharp & Dohme Limited	Use of nk-1 receptor antagonists for treating aggressive behaviour disorders
CA2298777A1 (en) *	1997-08-04	1999-02-18	Merck Sharp & Dohme Limited	Use of nk-1 receptor antagonists for treating mania
US6979456B1 (en)	1998-04-01	2005-12-27	Jagotec Ag	Anticancer compositions
GB9812662D0 (en) *	1998-06-11	1998-08-12	Merck Sharp & Dohme	Therapeutic use
GB9812617D0 (en) *	1998-06-11	1998-08-12	Merck Sharp & Dohme	Therapeutic use
GB9816897D0 (en) *	1998-08-04	1998-09-30	Merck Sharp & Dohme	Therapeutic use
EP1105096B1 (en)	1998-08-19	2003-10-29	Skyepharma Canada Inc.	Injectable aqueous dispersions of propofol
GB9902881D0 (en) *	1999-02-09	1999-03-31	Merck Sharp & Dohme	Therapeutic agents
KR100885986B1 (ko)	1999-11-03	2009-03-03	에이엠알 테크놀로지, 인크.	노르에피네프린, 도파민 및 세로토닌의 재흡수를 방지하기위한 아릴 및 헤테로아릴 치환된테트라하이드로이소퀴놀린 및 이들의 용도
US7163949B1 (en)	1999-11-03	2007-01-16	Amr Technology, Inc.	4-phenyl substituted tetrahydroisoquinolines and use thereof
GB0004699D0 (en)	2000-02-28	2000-04-19	Merck Sharp & Dohme	Chemical synthesis
US20050042194A1 (en)	2000-05-11	2005-02-24	A.P. Pharma, Inc.	Semi-solid delivery vehicle and pharmaceutical compositions
KR100821410B1 (ko)	2000-07-11	2008-04-10	에이엠알 테크놀로지, 인크.	4-페닐 치환된 테트라하이드로이소퀴놀린 및 이의치료학적 용도
GB0017256D0 (en)	2000-07-13	2000-08-30	Merck Sharp & Dohme	Therapeutic agents
DE10040051A1 (de) *	2000-08-11	2002-02-21	Basf Ag	Derivate des 4-(Trifluormethyl)-phenols sowie Derivate des 4-(Trifluormethylphenyl)-2-(tetrahydropyranyl)ethers und Verfahren zu ihre Herstellung
US20020103110A1 (en) *	2001-01-26	2002-08-01	Spitzer A. Robert	System and method for rectal administration of medication for treatment of migraines
GB0108973D0 (en) *	2001-04-10	2001-05-30	Merck Sharp & Dohme	Therapeutic agents
GB0121874D0 (en) *	2001-09-10	2001-10-31	Merck Sharp & Dohme	Therapeutic agents
US6673792B1 (en) *	2002-07-11	2004-01-06	Upchuck, Llc	Broad-spectrum anti-emetic compositions and associated methods
US7442698B2 (en)	2003-07-24	2008-10-28	Amgen Inc.	Substituted heterocyclic compounds and methods of use
AU2005274927B2 (en)	2004-07-15	2011-11-03	Albany Molecular Research, Inc.	Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
US7956050B2 (en)	2005-07-15	2011-06-07	Albany Molecular Research, Inc.	Aryl- and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
AU2006297443B2 (en)	2005-09-29	2010-08-12	Merck Sharp & Dohme Corp.	Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
AU2007300627B2 (en)	2006-09-22	2012-02-16	Merck Sharp & Dohme Corp.	Method of treatment using fatty acid synthesis inhibitors
WO2008090114A1 (en)	2007-01-24	2008-07-31	Glaxo Group Limited	Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-)
JP5319518B2 (ja)	2007-04-02	2013-10-16	Ｍｓｄ株式会社	インドールジオン誘導体
US9156812B2 (en)	2008-06-04	2015-10-13	Bristol-Myers Squibb Company	Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
US9034899B2 (en)	2009-05-12	2015-05-19	Albany Molecular Research, Inc.	Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
JP5764553B2 (ja)	2009-05-12	2015-08-19	アルバニーモレキュラーリサーチ，インコーポレイテッド	７−（［１，２，４］トリアゾロ［１，５−ａ］ピリジン−６−イル）−４−（３，４−ジクロロフェニル）−１，２，３，４−テトラヒドロイソキノリンおよびその使用
JP5739415B2 (ja)	2009-05-12	2015-06-24	ブリストル−マイヤーズスクウィブカンパニー	（Ｓ）−７−（［１，２，４］トリアゾロ［１，５−ａ］ピリジン−６−イル）−４−（３，４−ジクロロフェニル）−１，２，３，４−テトラヒドロイソキノリンの結晶形態およびその使用
CN105209436B (zh)	2013-03-15	2019-02-01	南洋理工大学	3-哌啶酮化合物及其作为神经激肽-1(nk1)受体拮抗剂的用途
US20230266304A1 (en) *	2020-07-15	2023-08-24	St. Jude Children's Research Hospital, Inc.	Obese ferret model and methods of establishing and using the same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5869496A (en) *	1993-01-28	1999-02-09	Merck & Co., Inc.	Spiro-substituted azacycles as tachykinin receptor antagonists
CA2157117C (en) *	1993-03-04	1999-01-05	Manoj C. Desai	Spirocyclic piperidine derivatives
AU680020B2 (en) *	1993-06-07	1997-07-17	Merck & Co., Inc.	Spiro-substituted azacycles as neurokinin antagonists
GB9417956D0 (en) *	1994-09-02	1994-10-26	Merck Sharp & Dohme	Therapeutic agents
GB9426103D0 (en) *	1994-12-23	1995-02-22	Merck Sharp & Dohme	Therapeutic agents
WO1997019084A1 (en) *	1995-11-23	1997-05-29	Merck Sharp & Dohme Limited	Spiro-piperidine derivatives and their use as tachykinin antagonists

1997
- 1997-06-17 SK SK1753-98A patent/SK175398A3/sk unknown
- 1997-06-17 EA EA199900045A patent/EA001574B1/ru not_active IP Right Cessation
- 1997-06-17 NZ NZ332777A patent/NZ332777A/en unknown
- 1997-06-17 PL PL97330235A patent/PL330235A1/xx unknown
- 1997-06-17 IL IL12690097A patent/IL126900A0/xx unknown
- 1997-06-17 KR KR1019980710463A patent/KR20000022060A/ko not_active Withdrawn
- 1997-06-17 EP EP97926140A patent/EP0906315A1/en not_active Withdrawn
- 1997-06-17 BR BR9709915A patent/BR9709915A/pt unknown
- 1997-06-17 CA CA002257964A patent/CA2257964A1/en not_active Abandoned
- 1997-06-17 JP JP10502496A patent/JP2000510153A/ja not_active Withdrawn
- 1997-06-17 US US09/202,493 patent/US6071927A/en not_active Expired - Fee Related
- 1997-06-17 YU YU59098A patent/YU59098A/sh unknown
- 1997-06-17 WO PCT/GB1997/001630 patent/WO1997049710A1/en not_active Ceased
- 1997-06-17 EE EE9800459A patent/EE9800459A/xx unknown
- 1997-06-17 TR TR1998/02667T patent/TR199802667T2/xx unknown
- 1997-06-17 AU AU31020/97A patent/AU722541B2/en not_active Ceased
- 1997-06-17 CZ CZ984247A patent/CZ424798A3/cs unknown
1998
- 1998-12-08 BG BG102998A patent/BG102998A/xx unknown
- 1998-12-18 NO NO985977A patent/NO985977L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
KR20000022060A (ko)	2000-04-25
EP0906315A1 (en)	1999-04-07
IL126900A0 (en)	1999-09-22
AU722541B2 (en)	2000-08-03
CA2257964A1 (en)	1997-12-31
TR199802667T2 (xx)	1999-03-22
NZ332777A (en)	2000-06-23
CZ424798A3 (cs)	1999-05-12
PL330235A1 (en)	1999-05-10
AU3102097A (en)	1998-01-14
EA199900045A1 (ru)	1999-06-24
NO985977L (no)	1999-02-22
US6071927A (en)	2000-06-06
BG102998A (en)	1999-09-30
SK175398A3 (en)	2000-04-10
EE9800459A (et)	1999-06-15
YU59098A (sh)	2002-06-19
JP2000510153A (ja)	2000-08-08
NO985977D0 (no)	1998-12-18
WO1997049710A1 (en)	1997-12-31
EA001574B1 (ru)	2001-06-25

Publication	Publication Date	Title
BR9709915A (pt)	1999-08-10	Composto composição farmacêutica utilização do composto e processos para o tratamento ou a prevençao de distúrbios fisiológicos asociados com um excesso de taquiquininas e para preparação do composto
BR9507656A (pt)	1997-09-23	Composto utilização de um composto composição farmacéutica e processos para o tratamento de um paciente que sofre de dor e para a preparação de um composto
BR9710362A (pt)	1999-08-17	Composto formula-ao farmaceutica utiliza-ao de um composto processos de tratamento de um ser humano ou animal sofrendo de uma mediada por atividade anormal de cinase de proteina tirosina e para a prepara-ao de um composto
BR9610248A (pt)	1999-07-06	Composto composição farmacêutica processos para o tratamento da dor e para a preparação de um composto e uso do composto
BR9710359A (pt)	1999-08-17	Composto formulacao farmaceutica uso de um composto e processos para a preparacao de um composto e para tratamento de um individuo humano ou animal que esteja sofrendo de um disturbio mediado por atividade aberrante de tirosina cinase proteinica
BR9406128A (pt)	1996-02-27	Uso de um composto processo para o tratamento e/ou prevençao de distúrbios psicóticos composto composiçao farmacêutica processos para a preparaçao de um composto e de uma composiçao farmacêutica
BR9612309A (pt)	1999-07-13	Composto uso de um composto composição farmacêutica formulação farmacêutica de aerossol combinação e processos para o tratamento de um indivíduo humano ou animal com uma condição anti-inflamatória e/ou alérgica e para a preparação de um composto
BR9404203A (pt)	1995-07-04	Compostos, processo para a preparação dos mesmos, medicamento, uso dos ditos compostos e processo de tratamento ou prevenção de distúrbios nervosos centrais
FI20000720A7 (fi)	2000-03-29	Pitkitettyyn vapautumiseen perustuva tablettiformulaatio Parkisonin taudin hoitamiseksi
BR9407720A (pt)	1997-03-04	Composto composiçao farmacêutica e processo para a prevençao ou tratamento de pertubaçoes imunorreguladoras ou doenças que compreendem a administraçao do composto
BR9702147A (pt)	1999-07-20	Composição farmacéutica uso de uma composição farmacéutica e processo para o tratamento da dor associada com escarificação periodontal e para a preparação de uma composição farmacéutica
DE69736441D1 (de)	2006-09-14	Pharmazeutische zusammensetzung zur behandlung von neurologischen und neuropsychiatrischen erkrankungen
HUP0103856A3 (en)	2003-11-28	Pharmaceutical composition for the treatment of acute disorders
PT1181027E (pt)	2004-09-30	Composicao dietetica ou farmaceutica para utilizacao na prevencao ou tratamento de hiperoxaluria
CA2257976A1 (en)	1997-12-18	Compositions and methods for coating medical devices
BR9707003A (pt)	1999-07-20	Composto processos para preparar o mesmo para tratamento ou de prevenção de doenças do sistema endócrino e para a manufatura de medicamento coposção farmacêutica e utilização de um composto
BR9706822A (pt)	1999-03-23	Composição kit processo para tratamento de um distúrbio respiratório e utilização da composição do kit de formoterol de um sal ou solvato farmaceuticamente aceitável do mesmo e de budesonida
BR0209812A (pt)	2004-06-01	Uso de osteopontina para o tratamento e/ou a prevenção de doenças neurológicas
BR9504491A (pt)	1997-05-20	Composto composiçao farmacêutica métodos para a inibiçao do tip IV de fosfodiesterase e de tratar ou prevenir um estado precário de saude
EE200100179A (et)	2002-10-15	Farmatseutilised agendid Parkinsoni tõve, ADHD jamikroadenoomide raviks
BR9502471A (pt)	1996-05-21	Composto de guanidina processo para preparar um composto de guanidina composição farmaceutica uso de um composto de guanidina método para o tratamento profilático ou terapêutico de doenças e processo para preparar uma composição farmacêutica
BR9710376A (pt)	1999-08-17	Composto antiviral uso do mesmo composi-Æo farmac-utica e processo para tratamento antiviral profil tico ou terap-utico de um animal humano ou nÆo humano
BR9610733A (pt)	1999-07-13	Composto processos para a preparação do mesmo e para o tratamento de um mamífero composição farmacêutica e utilização de um composto
EE04493B1 (et)	2005-06-15	Tsüklopenteeni derivaadid, neid sisaldav farmatseutiline kompositsioon ning ühendite kasutamine ravimina inimestel esinevate motiliini retseptoriga seotud häirete raviks
BR9611234A (pt)	1999-07-13	Composto formulação farmacêutica uso do composto e processos para tratamento de uma dor e para a preparação de compostos

Legal Events

Date	Code	Title	Description
2005-11-01	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE A 6A,7A E 8A ANUIDADES.